PERTH, Australia, March 16, 2025 /PRNewswire/ — Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology, is pleased to announce positive Phase IIb clinical trial results for CimetrA®, a novel anti-inflammatory treatment. The study confirmed CimetrA®’s strong safety profile and demonstrated faster recovery times in COVID-19 patients.
Key Findings:
- No drug-related adverse events, reinforcing CimetrA®’s safety.
- Faster clinical improvement versus placebo, measured by the WHO Ordinal Scale.
- Reduced inflammation, with significant modulation of key inflammatory markers (IL-6, IL-1β, TNF-α, and more).
- Improved quality of life trends observed in CimetrA®-treated patients.
CEO Roby Zomer stated:
“These promising results highlight CimetrA®’s potential as a breakthrough treatment for inflammatory diseases beyond COVID-19. We are excited about its future clinical development.”
With these findings, Argent BioPharma continues to advance innovative therapies. One such therapy, CannEpil®, is an oral mucosal solution with a high-CBD, low-THC formulation. It is designed to reduce seizure frequency and severity while minimizing psychoactive effects. After years of clinical development, CannEpil® is making waves in the UK as part of a movement to transform severe epilepsy treatment. This further reinforces Argent BioPharma’s commitment to addressing global health challenges.
For further information, please contact:
Argent BioPharma
Roby Zomer
CEO & Managing Director
+61 8 6555 2950
[email protected]
Argent BioPharma
Rowan Harland
Company Secretary
+61 8 6555 2950
[email protected]
SOURCE Argent BioPharma Ltd.
